Tuesday Nov. 24, 2015
NIH-sponsored clinical trial of chikungunya vaccine opens
An experimental vaccine to protect against the mosquito-borne illness chikungunya is being tested in a Phase 2 trial sponsored by the National Institutes of Health. In a phase 1 trial of the candidate vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases, all 25 volunteers developed robust immune responses to the vaccine. The new trial will enroll 400 healthy adults at six sites in the Caribbean.
No hay comentarios:
Publicar un comentario